Publication | Closed Access

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab

Breast OncologyPathologic Tumor ResponseMedicinePathologyCancer GenomicsBreast CancerMolecular OncologyTp53 GenomicsDocetaxel-capecitabine ± TrastuzumabCancer GeneticsCancer TreatmentOncologyRadiation OncologyTumor Biology